Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

HIV/AIDS

Menu
Menu

Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge
 

Rilpivirine and Adolescents

for Health Care Providers

Rilpivirine Updates: Approved for Adolescents; Possible Risk of Depression

The U.S. Food and Drug Administration has approved rilpivirine for use in adolescents 12 to 18 years of age; it is not recommended for younger children. As in adults, it is suggested for use in ARV-naive individuals with HIV RNA levels of <=100,000 copies/mL. The dosage is 25 mg daily, to be taken with a meal, and of course in combination with other ARV medications.

The rilpivirine package label has been updated to include information about the possibility of depression--in preapproval studies, depressive disorders occurred in 9% of adults (1% had Grade 3 or 4 symptoms, the same as in the efavirenz comparator arm) and in 19% of adolescents (5.6% Grade 3 or 4; there was no comparator regimen).